“Major Depressive Disorder Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Major Depressive Disorder Market.
The Major Depressive Disorder Pipeline report embraces in-depth commercial, regulatory, and Major Depressive Disorder clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Major Depressive Disorder drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Major Depressive Disorder Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Major Depressive Disorder treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Major Depressive Disorder therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Major Depressive Disorder companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Major Depressive Disorder drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Major Depressive Disorder therapeutic market.
Analysis of Emerging Major Depressive Disorder Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Subcutaneous
-
Intravenous
-
Intramuscular
Molecule Type
Products have been categorized under various Molecule types such as
-
Bispecific Antibody
-
Peptides
-
Small molecule
-
Gene therapy
Learn How the Major Depressive Disorder Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight
Latest Clinical, Commercial, and Regulatory Developments in the Major Depressive Disorder Therapeutics Market
– On 5 June 2023, ANeuroTech announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a pivotal Phase IIIB trial of ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder (MDD). Phase IIIB will include secondary endpoints of improvements in cognitive function and the ability to feel pleasure, the first time these have been included in an anti-depression drug clinical trial. ANeuroTech expects to begin the trial later this year.
– On Feb. 06, 2023, Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of the major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD.
– On December 06, 2022, Vistagen (NASDAQ: VTGN) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of PH10, one of the Company’s investigational nasal sprays, for the treatment of the major depressive disorder (MDD).
Major Depressive Disorder Therapeutics Landscape
There are approx. 75+ key companies developing therapies for Major Depressive Disorder. Currently, SAGE Therapeutics is leading the therapeutics market with its Major Depressive Disorder drug candidates in the most advanced stage of clinical development.
Major Depressive Disorder Companies Actively Working in the Therapeutic Market Include:
-
GH Research
-
Praxis Precision Medicines
-
AbbVie
-
Gedeon Richter
-
Intra-Cellular Therapies
-
Bristol-Myers Squibb
-
Relmada Therapeutics
-
SAGE Therapeutics
-
Janssen Research & Development
-
Minerva Neurosciences
-
Takeda
-
Neurocrine Biosciences
-
Pherin Pharmaceuticals
And Many Others
Emerging and Marketed Major Depressive Disorder Drugs Covered in the Report Include:
-
SAGE-217: Sage Therapeutics
-
REL-1017: Relmada Therapeutics, Inc
-
Seltorexant: Minerva Sciences
-
SP-624: Sirtsei Pharmaceuticals, Inc.
-
SPL026: Small Pharma
-
PDC-1421: BioLite Inc
-
Aripiprazole: BristolMyers Squibb
-
Aplenzin: Valeant Pharmaceuticals
-
Emsam: Somerset pharmaceuticals
-
AXS-05: Axsome Therapeutics
-
Vraylar: AbbVie
-
LY03005: Luye Pharma
And Many Other
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Major Depressive Disorder Companies Working in the Market @
https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Major Depressive Disorder Treatment Patterns
4. Major Depressive Disorder – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Major Depressive Disorder Late Stage Products (Phase-III)
7. Major Depressive Disorder Mid-Stage Products (Phase-II)
8. Major Depressive Disorder Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Major Depressive Disorder Discontinued Products
13. Major Depressive Disorder Product Profiles
14. Major Major Depressive Disorder Companies in the Market
15. Key Products in the Major Depressive Disorder Therapeutics Segment
16. Dormant and Discontinued Products
17. Major Depressive Disorder Unmet Needs
18. Major Depressive Disorder Future Perspectives
19. Major Depressive Disorder Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Concussions Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Concussions market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Concussions market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/